Perhaps - but amgen already have the market.
Imagine how Amgen's shareholders would feel in 3 years when another one of their revenue streams flounders due to the inaction of management after being publicly called out by a relatively unknown asx bio. It's worth noting that carfilzomib's revenue has increased recently due to combination treatment with Darzalex (J&J).
Do we know anyone from J&J?
Perhaps - but amgen already have the market. Imagine how...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $268.0M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $92.06K | 57.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 1300 | 1 |
View Market Depth
| Last trade - 14.29pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.57 |
Change
-0.035 ( 1.88 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 5451 | ||
| Last updated 14.29pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |